Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 21, Issue 14, Pages 4058-4062Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2012.11.028
Keywords
PPI inhibitors; PPI stabilizers; Protein-protein interactions; Drug development; Chemical biology
Funding
- AstraZeneca
- Bayer CropScience
- Bayer Healthcare
- Boehringer Ingelheim
- Merck KGaA
Ask authors/readers for more resources
14-3-3 Proteins are eukaryotic adapter proteins that regulate a plethora of physiological processes by binding to several hundred partner proteins. They play a role in biological activities as diverse as signal transduction, cell cycle regulation, apoptosis, host-pathogen interactions and metabolic control. As such, 14-3-3s are implicated in disease areas like cancer, neurodegeneration, diabetes, pulmonary disease, and obesity. Targeted modulation of 14-3-3 protein-protein interactions (PPIs) by small molecules is therefore an attractive concept for disease intervention. In recent years a number of examples of inhibitors and stabilizers of 14-3-3 PPIs have been reported promising a vivid future in chemical biology and drug development for this remarkable class of proteins. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available